IMVT-1402

Phase 3Small molecule

IMVT-1402 is one of 132 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

131

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Graves DiseaseRecruiting

Rheumatoid ArthritisActive, not recruiting

Myasthenia GravisActive, not recruiting

Subacute Cutaneous Lupus ErythematosusActive, not recruiting

Primary Sjögren's SyndromeRecruiting

Cutaneous Lupus ErythematosusActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Graves DiseasePhase 2

Recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Myasthenia GravisPhase 3

Active, not recruiting

Subacute Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Primary Sjögren's SyndromePhase 2

Recruiting

Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

IMVT-1402

IImmunovant Sciences GmbH

Phase 3

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Cataflam

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Subacute Cutaneous Lupus Erythematosus

NCT06980805

Phase 2Recruiting

Graves Disease

NCT07018323

Q3 2027

Phase 2Active, not recruiting

Rheumatoid Arthritis

NCT06754462

Q2 2028

Phase 2Recruiting

Graves Disease

NCT06727604

Q4 2028

Phase 3Recruiting

Myasthenia Gravis

NCT07039916

Clinical

Trials by Indication[1]

Graves disease3 trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06727604·240 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07018323·210 enrolled

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Enrolling by invitation·IImmunovant Sciences GmbH·Phase 2·NCT07286006·372 enrolled

Myasthenia Gravis1 trial

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Recruiting·IImmunovant Sciences GmbH·Phase 3·NCT07039916·231 enrolled

Rheumatoid Arthritis1 trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06754462·120 enrolled

Primary Sjögren's Syndrome1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06979531·180 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07032662·162 enrolled

1 more indication

Subacute Cutaneous Lupus Erythematosus1 trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations

Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06980805·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for IMVT-1402. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMVT-1402 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMVT-1402. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunovant Sciences GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImmunovant Sciences GmbH

IMVT-1402

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Graves disease3 trials

Myasthenia Gravis1 trial

Rheumatoid Arthritis1 trial

Primary Sjögren's Syndrome1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Subacute Cutaneous Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News